nView medical

Operating

nView medical Inc.

Biotech · Salt Lake City, UT

nView medical partners with leading pediatric hospitals, offering AI-powered 3D imaging solutions designed to enhance surgical precision and workflow efficiency.

Post-money valuation ⓘ

$30.2M

As of Aug 2025 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price

Total raised

$1,661,831

Crowd $161K · Private $1.5M · 3 rounds since 2018

Latest share price

$8.31

Reg CF · Common Stock · Mar 2025 offering price

Financials

FY2022–FY2025 · from SEC filings · hover any figure for its source

$247K

−$1.7M

2022

2023

$905K

−$762K

2024

$1.1M

−$233K

2025

RevenueNet income — beside revenue when positive, below the line when a loss

Metric

FY2022 reviewed

FY2023 reviewed

FY2024 reviewed

FY2025 reviewed

Income statement

Revenue

$247,219

—

$905,306

$1,079,148

Cost of goods sold

$123,498

—

$375,704

$414,438

Gross margin

50%

—

58%

62%

Net income

-$1,669,253

—

-$761,579

-$233,384

Taxes paid

—

Balance sheet

Cash

$170,783

—

$149,059

$252,109

Accounts receivable

$49,442

—

$125,912

$61,645

Total assets

$1,019,696

—

$916,095

$820,301

Short-term debt

$1,537,297

—

$2,327,566

$2,615,292

Long-term debt

$4,728,040

—

$485,195

$119,183

Total liabilities

$6,265,337

—

$2,812,761

$2,734,475

Other

Headcount

—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in

$30.0M

pre-money

Reg CF · Common · Mar 2025

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Reg CF · Common Stock · Mar 2025Closedvia StartEngine

Raised $160.8K / $399.9KInvestors 156Post-money $30.2M

Rule 506(b) · Debt · May 2019Closed

Raised $1MInvestors 1

Rule 506(b) · Equity · Feb 2018Closed

Raised $501KInvestors 1

Team

8 people

Cristian Atria

CEO, Principal Accounting Officer

A healthcare entrepreneur with over 20 years of experience in product development and commercialization. Previously at GE Healthcare, he led major platform launches. Cristian holds multiple patents and advanced degrees in engineering and business.

Lisa Last

Chief Operating Officer

Bringing more than 20 years of experience, including 11 at GE Healthcare, Lisa leads nView’s regulatory, clinical and manufacturing operations. With expertise in systems design and FDA compliance, she has successfully overseen multiple product clearances and market entries.

Christopher von Jako, PhD

Board Member (Part Time)

A seasoned med-tech executive, Dr. von Jako has led companies like BrainsWay and Dynatronics, securing major investments and orchestrating various exits. His leadership spans strategic growth, investor relations, and medical imaging innovation. Christoper spends 2 hours per week on nView medical.

Frederic Noo, PhD

Scientific Advisor – Image Reconstruction

A tenured professor at the University of Utah, Dr. Noo is an international expert in medical imaging, with a focus on image reconstruction and system design. He has authored over 90 peer-reviewed papers and serves on multiple editorial boards.

Kevin Foley, MD

Board Member (Part Time)

A neurosurgeon and professor at the University of Tennessee, Dr. Foley has pioneered many advancements in spine surgery. With over 150 patents, he actively contributes and invests in surgical innovations. Kevin spends 6 hours per week with nView medical.

Tolga Tasdizen, PhD

Scientific Advisor - AI & Machine Learning

A professor at the University of Utah, Dr. Tasdizen is a renowned expert in machine learning, AI, computer vision and image analysis, with a focus on medical applications. He is chair of the Medical Imaging with Deep Learning conference (MIDL) and a recipient of the National Science Foundation's CAREER Award.

Christopher von Jako

Board Member

Kevin Foley

Board Member

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 1 of 2 annual reports (FY2024–FY2025)

156 investors

holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

Form C-ARApr 29, 20260001733353-26-000001
EDGAR
Form C/AJun 23, 20250001665160-25-001235
EDGAR
Form C-UApr 18, 20250001665160-25-000719
EDGAR
Form C/AApr 17, 20250001665160-25-000696
EDGAR
Form CMar 26, 20250001665160-25-000487
EDGAR
Form DMay 23, 20190001766219-19-000002
EDGAR
Form DMar 6, 20180001733353-18-000002
EDGAR

Source: SEC EDGARCIK 0001733353DEShare price $8.31Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.